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Summary Angiogenesis plays an important role in the growth and metastasis of solid tumours. Platelet-derived endothelial cell growth factor
(PD-ECGF) is known to be chemotactic for endothelial cells in vitro and angiogenic in vivo. It is also known as gliostatin, a factor promoting
neuronal survival, and thymidine phosphorylase (dThdPase), which catalyses the reversible phosphorylation of thymidine to thymine and
2-deoxyribose-1-phosphate. This enzymatic activity is critical for angiogenic activity. PD-ECGF protein is highly expressed in tumours
compared with most normal tissues and has been correlated with tumour growth, invasion and metastasis in clinical studies. In addition,
dThdPase activity (by inference PD-ECGF) has been found to be a major determinant of the toxicity of 5-fluorouracil and its prodrugs, which
are extensively studied clinically as anti-cancer agents. This review attempts to summarize recent gains in understanding the nature, location
and action of PD-ECGF and its specific relevance to tumour biology.
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The growth ofa solid tumour from a single aberrant cell can take a
few weeks or many decades. There are many stages in tumour
growth from the formation ofthe initial foci ofcells that constitute
the primary tumour to the eventual spread and formation of
secondary tumours at distant sites if the tumour is metastatic. One
key event in this progression is the formation ofafunctional vascu-
lature that can supply the tumour with oxygen and other nutrients.
This allows it to grow, but also provides an avenue of dissemina-
tion. Angiogenesis is a tightly controlled process normally
confined to embryogenesis, wound healing and the reproductive
cycle, but is also characteristic of several disease states including
rheumatoid arthritis, psoriasis and solid tumour growth. Tumours
cannot grow beyond a very limited size (1-2 mm3) unless angio-
genesis occurs, as diffusion of nutrients becomes limiting
(Folkman, 1986, 1990). There are many factors now known to be
capable of influencing angiogenesis, and antiangiogenic strategies
have been proposed to exploit this feature of the tumour environ-
ment (see Fan et al, 1995 for review). Factors promoting angiogen-
esis include acidic and basic fibroblast growth factor (aFGF and
bFGF), vascular endothelial growth factor (VEGF), angiogenin and
platelet-derived endothelial cell growth factor (PD-ECGF), many
ofthese being found to be abnormally elevated in the tumour envi-
ronment. Angiostatin, endostatin and thrombospondin are known
physiological angiogenic inhibitors, and it is the balance between
such opposing factors in the tumour environment that determines
the development of the vascular system within the tumour. PD-
ECGF is a relative newcomer to the field ofangiogenesis research,
and over recent years there have been significant additions to the
understanding of its location and action, particularly in tumour
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biology. This review summarizes the current knowledge on the
structure, function, location and action of PD-ECGF within the
tumour environment.
Vascularization of solid tumours is known to be poor and disor-
dered, leading to insufficient perfusion and diffusion ofnutrients to
areas of the tumour. This is thought to be a major reason for the
existence of hypoxia (low oxygen), glucose depletion and to a
lesser extent low pH within solid tumours. It is known that
microenvironmental factors, such as the above, can influence the
production of angiogenic growth factors such as VEGF, and may
be in partresponsible, along with the action ofotherfactors, forthe
observed elevations in expression of PD-ECGF (Griffiths et al,
1997). VEGF expression can be regulated by the products of acti-
vated oncogenes and mutant or deleted tumour-suppressor genes,
cytokines, hormonal modulators and hypoxia (see Claffey et al,
1996 forreview). PD-ECGF has many roles (Figure 1). It is known
to stimulate endothelial mitogenesis and chemotaxis in vitro and
promote angiogenesis. It is reported to be a 90-kDa protein dimer,
first purified as the sole endothelial mitogenic activity in platelets
(Miyazono et al, 1987), but since found in many other tissues and
cells, including placenta and macrophages (Yoshimura et al, 1990).
Levels are found to be elevated in solid tumours, rheumatoid
arthritis synovium (Asai etal, 1993) and psoriatic lesions (Creamer
et al, 1996). PD-ECGF is known not to bind heparin, in contrast to
the other angiogenic factors aFGF, bFGF and VEGF (except splice
variant 121) (Miyazono et al, 1987). When overexpressed in MCF-
7 cells, PD-ECGF resulted in an increase in tumour growth and
was found to be angiogenic in the rat sponge and freeze-injured
skin graft models (Moghaddam et al, 1995). Gliostatin, which is a
neurotrophic factor produced by quiescent astrocytes, has also
been shown to be a form of PD-ECGF. It acts as an inhibitory
growth regulator against all glial tumour cells and glial maturation
fac.tor-stimulated astroblasts, but not ofneuronal cells. These func-
tions have suggested that PD-ECGF may have a significant role in
the development and regeneration of the nervous system and be
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involved in the induction of angiogenesis for the formation of the
blood-brain barrier (Asai et al, 1992a,b).
GENE STRUCTURE
Ishikawa et al (1989) isolated a 1.8-kb full-length cDNA
sequence of PD-ECGF using poly(A)+ RNA from term placenta,
predicting a protein consisting of482 amino acid residues. Amino
acid sequencing of the protein identified 389 residues giving a
predicted molecular weight of48.6-49 kDa. The cDNA sequence
showed a GC rich 5' untranslated area and the lack of a hydro-
phobic signal sequence. This suggested that PD-ECGF is not a
classic secretory protein. However, bFGF and aFGF, which also do
not have a signal, are secreted via aprotein kinase C (PKC) depen-
dent phosphorylation mechanism and PD-ECGF is known to have
a putative PKC binding site (Usuki et al, 1991), but it is not known
whether this is the mechanism ofits secretion. Also ofinterest was
the identification of two short internal repeats and two nucleotide
binding motifs (Gly-X-Gly-X-X-Gly). Seven cysteine residues
were found, indicating that PD-ECGF has at least one free thiol
group and one potential glycosylation site, but it appears from
comparison with the predicted Mt and theMt obtained by SDS-gel
electrophoresis that it is not glycosylated.
The PD-ECGF gene is composed of ten exons dispersed over a
4.3-kb region, with the translation start codon in exon 2 and the
stop codon (within the polyadenylation signal) in exon 10. The
promoter lacks a 'TATA' box and a 'CCAAT' box commonly
found in eukaryotic promoters. It does however contain six copies
ofbinding motifs ofthe SP-1 general transcription factor upstream
ofthe transcription start site (Hagiwara et al, 1991).
Nucleotidylation of PD-ECGF can occur by covalent binding of
serine residue(s) to the phosphate groups ofnucleotides and the two
nucleotide binding motifs may be involved in the reaction (Usuki et
al, 1991). The physiological significance of this may be explained
by the enzyme activity now attributed to PD-ECGF (below).
THYMIDINE PHOSPHORYLASE ACTIVITY
In 1992, Barton et al found PD-ECGF to have a 40% sequence
similarity to thymidine phosphorylase (dThdPase) of Escherichia
coli. Thymidine phosphorylase activity of PD-ECGF was
confirmed by Usuki et al (1992) and Moghaddam et al (1992).
However, although we (in this review) and many others use PD-
ECGF/dThdPase interchangeably, the sequence comparison of
human dThdPase to human PD-ECGF has not been reported.
dThdPase is an enzyme specifically involved in the reversible
dephosphorylation of thymidine to thymine and 2-deoxyribose-1-
phosphate (Zimmerman and Sidenberg, 1964). The optimumpH for
this activity was found to be 5.3 (Finnis et al, 1993). Site-directed
mutagenesis of the PD-ECGF gene subsequently transfected into
COS cells has shown that the enzymatic activity is essential to the
angiogenic activity ofPD-ECGF/dThdPase (Miyadera et al, 1995).
This is not a phenomenon restricted solely to PD-ECGF/dThdPase:
another angiogenic growth factor, angiogenin, also has enzymatic
(ribonuclease) activity, which seems to be at least partially respon-
sible for its angiogenic effect (Shapiro et al, 1989).
PD-ECGF/dThdPase may promote angiogenesis by reducing
thymidine levels inhibitory to endothelial proliferation because of
the use ofthe thymidine salvage pathway when intracellular thymi-
dine pools are depleted (Finnis et al, 1993), or alternatively the
enzymatic products of PD-ECGF/dThdPase, namely thymine
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Figure 1 The roles of PD-ECGF/TP
and 2-deoxyribose-1-phosphate or metabolic/catabolic products
derived from them may themselves be angiogenic. Indeed,
although no angiogenic activity has been ascribed to thymine, 2-
deoxy-D-ribose, a dephosphorylated product of 2-deoxyribose-1-
phosphate has been found to have angiogenic and chemotactic
activity (Haraguchi et al, 1994). Studies on murine (liver), and
human (placental and liver) PD-ECGF/dThdPase have shown inter-
and intraspecies differences in substrate specificities for natural
and 5-fluoropyrimidine compounds and have suggested that the
hydrophobicity ofthe human enzymes when measured atpH 8 (not
the optimum, Finnis et al, 1993) are different from their murine
counterparts (Elkouni et al, 1993).
Other nucleoside phosphorylases including uridine phosphory-
lase (UrdPase), and purine nucleoside phosphorylase (PNP) have
been identified in mammalian tissues. UrdPase catalyses the break-
down of uridine to uracil and D-ribose sugar (not thought to be
angiogenic (Haraguchi et al, 1994). PNP can breakdown guanosine
to guanine and D-ribose.
IN VIVO LOCALIZATION OF PD-ECGF/dThdPase
Extensive immunohistochemical studies ofthe location and abun-
dance of PD-ECGF/dThdPase in normal human tissues have been
carried out. Expanding on earlier work with liver, lung and
placenta (Usuki et al, 1990; Yoshimura et al, 1990), Fox et al
(1995) demonstrated immunohistochemical staining for PD-
ECGF/dThdPase within the nuclear and cytoplasmic regions.
The predominant cells staining for PD-ECGF/dThdPase were
macrophages, although many other cell types were also positive;
for example skin, Kupffer cells, alveolar macrophages, placental
stromal cells and endothelial cells in placenta, ovary, salivary
gland and brain. Lymphoid cells were found to be negative,
although lymphocytes have been found to be positive in other
studies (Takebayashi et al, 1996a). The lack ofconsistent staining
in areas where normal angiogenesis would be expected (e.g.
placenta) suggested a role for PD-ECGF in pathological but not
physiological angiogenesis. This is consistent with the observation
ofhigh expression in macrophages, which are recruited in wound
healing, the inflammatory response and in tumours. Further,
platelets, also recruited in wound healing, are a substantial source
of PD-ECGF/dThdPase and thus suggest a role for it in mainte-
nance of the vasculature. PD-ECGF/dThdPase has also been
suggested to have a role in differentiation of certain cell types
(Yoshimura et al, 1990; Heldin et al, 1993; Fox et al, 1995).
PDECGF/dThdPase EXPRESSION IN TUMOURS
Histological analyses in a variety of human tumours, including
breast (Moghaddam, 1995; Toi et al, 1995), bladder (O'Brien et al,
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Figure 2 Schematic diagram of PD-ECGF/TP involvement in tumour growth processes
1995), ovarian (Reynolds et al, 1994) gastric (Takebayashi et al,
1996b; Maeda etal, 1996) oesophageal, lung, pancreas (Takebayashi
et al, 1996c) and colorectal cancers (Takebayashi et al, 1996a;
Takahashi et al, 1996; Saeki et al, 1996) have shown elevated
PD-ECGF/dThdPase levels. It has been shown to be a prognostic
indicator in colorectal and gastric cancers (Takebayashi et al, 1996
a,b,c). It has also been correlated with microvessel density in breast
(Toi et al, 1995), colon (Takahashi et al, 1996; Takebayashi et al,
1996c), and gastric cancers (Takebayashi et al, 1996b; Maeda et al,
1996), providing evidence that it is a major contributor to the
formation and maintenance ofthe tumour vasculature.
A significant presence of PD-ECGF/dThdPase in invasion and
metastasis has been found in ovarian (Reynolds et al, 1994),
gastric (Takebayashi et al, 1996b) and colorectal (Takebayashi et
al, 1996c) cancers whereas the production of PDECGF/dThdPase
by infiltrating cells has been investigated in colon (Takehashi et al,
1996) and breast (Fox et al, 1996) and found to contribute to
overall tumour levels.
Elevated thymidine phosphorylase enzyme activity has been
reported in breast tumours (Patterson et al, 1995) and has also been
detected in plasma of tumour-bearing animals and humans (Pauly
et al, 1977, 1978). It is not clear whether this is due to its release
from the tumour itself or production and release by host cells and
tissues in response to tumour growth/proliferation.
Activity of another pyrimidine phosphorylase, UrdPase, has
also been reported to be elevated in primary human tumours,
including colon (Luccioni et al, 1994) and melanoma (Leyva et al,
1983). One study in human colon carcinoma has suggested PNP
activity is also enhanced and suggests a positive relationship with
enzyme activity and tumour invasiveness (Sanflippo et al, 1994).
Thus, there may be a link between the activity of nucleoside
phosphorylases generally and angiogenesis, but this remains to
be established.
REGULATION OF PD.ECGF/dThdPase
In contrast with angiogenic growth factors such as VEGF, the basis
of tumour-specific elevation of PD-ECGF/dThdPase levels is
currently not well understood. Cytokines or growth factors, such
as interleukin (IL-1), tumour necrosis factor (TNF) bFGF, IFN-y
and IFN-a that are known to increase dThdPase activity (Eda et al,
1993a; Tevaerai et al, 1992) may play a role, or additionally/alter-
natively the influence of microenvironmental factors such as
hypoxia and low pH (Griffiths et al, 1997) may be important
(Figure 2). Indeed, solid tumours, rheumatoid arthritis and psori-
atic conditions (all of which have been identified as conditions
with elevated VEGF and PD-ECGF/dThdPase) are known to be
associated with the development of hypoxia and aberrant angio-
genesis. The effect ofother factors that might influence PD-ECGF
expression, e.g. the products of oncogenes and tumour-suppressor
genes have yet to be established.
The role ofPD-ECGF in vivo is still somewhat unclear. The high
expression in lymphoid tissue and skin may be important for total
body thymidine homeostasis (see Fox et al, 1995). As the largest
source of PD-ECGF in the body is found in platelets, this strongly
suggests that it has a role in maintaining the integrity of blood
vessels, promoting therepairoftheendothelium. The netincreases in
vasculature, seen when PD-ECGF is overexpressed, may be caused
largely by stabilizing and maintaining the existing vasculature.
PDECGF/dThdPase IN CHEMOTHERAPY
PD-ECGF/dThdPase is known to be elevated in tumours compared
with surrounding normal tissue (though absolute comparison with
levels present in normally high-expressing cells, such as platelets,
is difficult as most published studies have been histological). This
apparent differential makes dThdPase an attractive target for
chemotherapy.
5 fluorouracil (5-FU) has been extensively studied and is used
routinely in the treatment of a variety of tumour types, e.g. colon,
breast. dThdPase may play a role in the therapeutic application of
5-FU because it is known to catalyse the conversion ofthe pyrimi-
dine antimetabolite 5-FU to 5'-fluoro-2'-deoxyuridine (5'-FdUR)
by the addition of 2-deoxyribose-1-phosphate (Figure 3). This is
the first step in one pathway for the metabolic activation ofthe 5-
FU agent to deoxyribonucleotides (Iltzsch et al, 1985). Ultimately
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Figure 3 Reactions catalysed by PD-ECGFfTP
metabolites ofthese drugs can inhibit thymidylate synthase, either
by restricting de novo synthesis of nucleotides, or by fraudulent
incorporation into DNA, or both (Schwartz et al, 1992).
If 2-deoxyribose-l-phosphate is the molecule responsible for
PD-ECGF/dThdPase-stimulated angiogenesis, then 5-FU fulfils a
dual role: it can disrupt DNA synthesis by the production of 5'-
FdUR and in doing so also removes potentially angiogenic mole-
cules from the tumour environment. In theory, this would lend its
use to more aggressive and metastatic diseases, often character-
ized by a more angiogenic phenotype.
Fujimoto et al (1985) also showed that dThdPase was important
in the conversion of 5'-deoxy-5-fluorouridine (5'-DFUR) (an
analogue ofthymidine and aprodrug of5-FU) to 5-FU, which was
later confirmed by studies with cells overexpressing dThdPase;
cells with a 90-fold increase in dThdPase activity showed a 165-
fold increase in sensitivity to 5'-DFUR, whereas in this study
sensitivity to 5-FU itselfwas not affected (Patterson et al, 1995).
In vitro studies have demonstrated the potentiation of5-FU and
5'-DFUR toxicity by IFN-a, as it can elevate dThdPase levels
(Schwartz et al, 1995 and Tevaerai et al, 1992 respectively).
Clinical trials of patients with metastatic colorectal carcinoma
treated with 5-FU and IFN-a have shown an increase in response
rates over controls treated with 5-FU alone (Wadler et al, 1989).
These effects are presumed to be the result of increases in
dThdPase expression owing to the action of IFN-a causing
enhanced metabolic activation of 5-FU. However, in this context,
the use of IFN-a presents some incongruities. It is reported to be
an inhibitor of angiogenesis, so it would seem that the antiangio-
genic effect ofIFN-a together with its ability to induce dThdPase
and thereby increase the activation of5FU may be more important
than the potentially proangiogenic effect ofthe elevated dThdPase
in the outcome ofclinical treatment.
Interestingly, UrdPase is also capable ofconverting 5'-DFUR to
5-FU and, like dThdPase, is inducible by TNF-a, IL-la and
IFN-y (Eda et al, 1993b). This suggests both a functional and a
co-regulatory relationship between dThdPase and UrdPase.
Another avenue for chemotherapy targeted at dThdPase may be
through the inhibition ofthymidine phosphorylase enzyme activity
and therefore its angiogenic properties. It has been shown that a
dThdPase inhibitor (6-amino-5-chlorouracil) inhibits the angio-
genic activity ofpurified dThdPase in vitro (Miyadera et al, 1995).
Inhibition at nanomolar concentrations has been reported for
related enzymes such as UrdPase (Naguib et al, 1993). Known
inhibitors of dThdPase are less potent than those for UrdPase, the
most effective being 6-aminothymine (Woodman et al, 1980) and
6-amino-5-bromouracil (Desgranges et al, 1982). Alternative
substrates for dThdPase have also been considered as inhibitors
(Desgranges et al, 1983), and may be of further use in antiangio-
genic therapy ofcancer.
SUMMARY
The study of PD-ECGF/dThdPase is now a very active area in in
vitro, in vivo and clinical research. It is one ofthe few angiogenic
growth factors that, in addition to being overexpressed in the
tumour environment, also provides a large scope for chemo-
therapeutic exploitation, combining antiangiogenic and anti-
proliferative treatment regimens. However, the presence of
PD-ECGF/dThdPase in other tissues and blood would make the
development of specifically tumour-targeted therapy preferable.
Very little is known about its gene expression, although emerging
evidence suggests that both cytokine/growth factor and physico-
chemical/microenvironmental stimuli can influence protein levels
and activity. The absolute reliance on the enzymatic nature ofPD-
ECGF/dThdPase for its angiogenic properties is unique, and the
possible importance of UrdPase and PNP, enzymes with similar
functions, remains to be determined. This has led to questions
about the specific role of PD-ECGF in tumour angiogenesis and
angiogenesis in other disease states, along with exactly how it
stimulates endothelial mitogenesis and chemotaxis.
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